Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments

Alpha Cognition Inc. (NASDAQ: ACOG) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. The commercial-stage biopharmaceutical company's participation highlights the conference's focus on innovative companies positioned for long-term growth, particularly in the healthcare sector where Alpha Cognition is developing treatments for neurodegenerative diseases.

The company specializes in addressing Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), both conditions that currently lack approved treatment options. This makes Alpha Cognition's research and development efforts particularly significant for the millions of patients and families affected by these neurological conditions worldwide.

Michael McFadden, CEO of Alpha Cognition, emphasized the importance of the conference platform for sharing the company's progress. "We are excited to share our company's story with such a distinguished audience of investors and peers," McFadden stated. "The Spartan Capital Conference offers a unique platform to highlight our commercial and pipeline progress, connect with new investors, and strengthen relationships within the capital markets community."

Spartan Capital Securities Founder and CEO John D. Lowry expressed enthusiasm about featuring Alpha Cognition at the event. "We are delighted to feature Alpha Cognition at our second annual investor conference," Lowry said. "Spartan Capital has built its reputation on helping growth companies access the right investors and resources, and this conference is a powerful extension of that mission - bringing together high-quality issuers and serious capital providers under one roof."

The conference, organized in partnership with B2i Digital, will showcase more than 60 carefully selected companies across multiple high-growth sectors including technology, healthcare, consumer goods, mining, and precious metals. Over 500 institutional and high-net-worth investors are expected to attend the event, which represents a significant opportunity for emerging companies to gain visibility and secure funding.

David Shapiro, CEO of B2i Digital, explained the selection process for conference participants. "In collaboration with Spartan Capital's banking team, we invited Alpha Cognition to share their perspective with the investors in attendance," Shapiro noted. "Their participation is part of our broader commitment to connecting investors with a diverse range of growth companies, supporting B2i Digital's core mission - combining the broad reach of digital marketing with the powerful impact of face-to-face investor engagement."

The event format includes main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions designed to facilitate meaningful dialogue between growth companies and the investment community. For more information about the conference and registration details, please visit https://spartancapital.com.

Alpha Cognition's focus on neurodegenerative diseases represents a critical area of medical need, given the aging global population and increasing awareness of brain health issues. The company's research into Alzheimer's Disease treatments comes at a time when the World Health Organization estimates that nearly 10 million new cases of dementia are diagnosed each year globally, with Alzheimer's Disease contributing to 60-70% of these cases.

Similarly, the company's work on cognitive impairment related to mild traumatic brain injury addresses a growing concern in sports medicine, military health, and general neurology. With increasing recognition of the long-term consequences of concussions and head injuries, effective treatments for mTBI-related cognitive issues could have substantial impact across multiple patient populations.

The investor conference presentation provides Alpha Cognition with an opportunity to demonstrate its progress in these challenging therapeutic areas to potential investors who recognize the significant market potential for successful neurodegenerative disease treatments. The pharmaceutical industry has seen increased investment in neurological disorders as understanding of brain function and disease mechanisms has advanced, though developing effective treatments remains scientifically complex and capital-intensive.

Success in developing treatments for conditions with no current pharmaceutical options could not only provide substantial returns for investors but also address significant unmet medical needs affecting millions of patients worldwide. The conference serves as a crucial platform for companies like Alpha Cognition to secure the funding necessary to advance their research through clinical trials and potential regulatory approval processes.